Mitomycin C in complicated trabeculectomy: A prospective comparison of 0.2 to 0.4 mg/cc

S. P. Sanders, L. B. Cantor, A. A. Dobler, J. S. Hoop, W. E. Sponsel

Research output: Contribution to journalReview articlepeer-review


Purpose: To compare the efficacy and safety of 0.7 to 0.4 mg/cc Mitomycin C (MMC) in tiabeculectomy of eyes that have undergone previous incisonal surgery. Methods: 50 eyes requiring trabeculectomy were randomized in a masked, prospective study to receive either 0.2 or 0.4 mg/cc of MMC for two minutes. All eyes had undergone prior incisional surgery. Intraocular pressure, logMAR visual acuity, and complications were monitored at regular intervals for one year. The percent decrease in IOP was compared in unpaired student t-test. There were no significant differences in IOP, age, sex, and race between groups. Results: Percent Decrease in IOP logMAR Va Pre-op 1week 2month 6month 1year 1mon 6mon 1year 0.2mg/cc 29mmHg 80.0% 52.1% 48.4% 46.0% -.74 -.52 -.69 0.4 mg/cc 25mmHg 76.0% 45 0% 42.4% 47.3% -.73 -.39 -.49 p-value 0.25 0.31 0.81 0.65 0.78 0.92 0.53 0.45 Incidence of hypotony, choroidal effusions/hemorrhages, and wound leaks was similar between groups. One bleb (4%) in the 0.2mg/cc and two blebs (8%) in the 0.4mg/cc group failed completely. Conclusions: The data suggests similar efficacy and safety with 0.2 or 0.4 mg/cc MMC in complicated trabeculectomies.

Original languageEnglish (US)
Pages (from-to)S25
JournalInvestigative Ophthalmology and Visual Science
Issue number3
StatePublished - Feb 15 1996

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Mitomycin C in complicated trabeculectomy: A prospective comparison of 0.2 to 0.4 mg/cc'. Together they form a unique fingerprint.

Cite this